Our mission is to provide patients and physicians with NeuroScreen®, our novel, blood-based test for the early detection of Alzheimer's Disease. 

Alzheimer’s disease is a neurodegenerative disorder that gradually impairs memory, cognitive function, and behavior, primarily affecting older adults. It is defined by the accumulation of amyloid plaque (Aβ) in the brain, even before the appearance of symptoms. Recent studies have learned that Aβ accumulation can begin up to 20 years before symptoms appear, but there has been no effective way to identify patients until now.

To meet that need, NeuroQuest developed NeuroScreen® - the only blood based assay that can accurately track Aβ accumulation at all disease stages. Early detection will allow patient-centric medical decisions to be made by physicians and was shown to enhance treatment efficiency.

NeuroQuest Ltd.

Org chart

Teams

Offices

NeuroQuest Ltd.

Org chart

Teams

Offices

Related companies